Discover how Concept Foundation has leveraged high-quality and verified data to increase their confidence in applications, as well as reducing the time spent planning the chemistry, manufacturing and controls (CMC) module for regulatory submissions.
Identifying and evaluating new products to rise above the competition
Learn how the Business Development and Licensing team help Par Pharmaceutical rise above the competition by quickly and accurately identifying a shortlist of potential portfolio candidates, recognizing potential barriers to market entry, and monitoring the launch, API development and patenting activities of competitors worldwide.
Making data driven decisions with reliable intelligence
Johnson & Johnson experienced difficulties keeping up to date on the global drug pipeline and spent considerable time and expense gathering and analyzing data from multiple sources. Discover how Cortellis Competitive Intelligence helped the company apply reliable data to confidently make strategic decisions.
Securing the best price for an out-licensed asset
Biotech Ensysce seeks out-licensing or partnering opportunities around the world for its proprietary abuse and overdose resistant prodrug technologies. Learn how the company has made successful deals faster, without sacrificing due diligence, and negotiated a higher price than what it originally thought it could obtain.
Confidently complying with global regulatory guidelines
Find out how the regulatory team at Paion make data-driven, informed decisions related to regulatory strategy, confidently comply with regulatory guidelines and save time and money tracking regulatory changes.
Understanding when a drug can become generic
See how API manufacturer Dipharma has grown its business by gaining insight as to when drugs can go generic and reducing the workload for generic portfolio selection.
Conducting pathway analyses to accelerate discovery research
Discover how researchers at Harvard University freed up the bioinformatics team by empowering biologists to analyze their own data, and made critical go/no-go decisions regarding which drugs to push through the development lifecycle by obtaining an understanding of omics data in the context of their therapeutic area
Drug repurposing for rare disease treatment leads to reduced risk
Director of the Drug Discovery Platform of Parc Científic Barcelona, Jordi Quintana and his team secured funding to investigate a rare disease, amyloidosis. They set out to study a subset of the disease called familial amyloid polyneuropathy. Because of the rare nature of the disease and the limited patient base, traditional drug discovery and development […]
Understanding the clinical competitive landscape
To measure its progress against other companies in its therapeutic space, a small U.S. biopharma needed to understand the biomarkers these competitors used, the endpoints established, and their likely impact on clinical trial success. In this case study, see how the company’s clinical team used Cortellis Clinical Trials IntelligenceTM to gain competitive insight that helped […]
Tapping into essential rare disease trial data
Relying on manual searches through public sources was increasingly time-consuming and insufficient, the information manager at a global rare disease specialist determined. To help her respond to the flow of requests for clinical trials information from her investigators, she needed a source of rich, trusted clinical trials data– one that had a depth of coverage […]
